A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.

Integr Cancer Ther · 2022 · PMC8943553 · PMID 35313775

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

If the result of testing showed a trend of yes (but no clear yes), the physician would perform tongue diagnostics according to TCM guidelines, and if this examination showed Qi insufficiency constitution, the patient was included in the study provided the other inclusion/exclusion criteria are fulfilled.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.